(Solid Tumors) M6620 (VX-970) Monotherapy and Combination Therapy Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On June 22, 2020, Timothy A. Yap published in the medical journal Journal of Clinical Oncology the efficacy and safety results of ATR inhibitor M6620 (VX-970) monotherapy and M6620 + carboplatin combination therapy in previously treated patients with advanced solid tumors in a Phase 1 clinical trial.
This Phase 1 trial randomly assigned previously treated patients with advanced solid tumors into two groups. Primary endpoint: safety and tolerability; secondary endpoint: anti-tumor activity.
- M6620 (VX-970) monotherapy group (1–2 times per week, M6620 60–240 mg/m²; N=17)
- M6620 (VX-970) combination therapy group (once per week, M6620 90–240 mg/m² + carboplatin; N=23)
Safety results: Grade 3 or higher adverse events — M6620 monotherapy group 5.9% (N=1); M6620 combination group 30.4% (N=7). Overall adverse event rate — M6620 monotherapy group 88.2% (N=15); M6620 combination group 91.3% (N=21).
Based on these safety results, the recommended Phase 2 doses were determined: M6620 monotherapy group (1–2 times per week, M6620 240 mg/m²); M6620 combination group (once per week, M6620 90 mg/m² + carboplatin).
Anti-tumor efficacy results (secondary endpoint): In the M6620 monotherapy group (N=17 evaluable): 1 complete response, 5 stable disease. In the M6620 combination group (N=21 evaluable): 1 partial response, 15 stable disease.
Based on Phase 1 trial results, Timothy A. Yap concluded: In previously treated patients with advanced solid tumors, ATR inhibitor M6620 (VX-970) monotherapy and M6620 + carboplatin combination therapy showed good tolerability and confirmed anti-tumor activity.
Source: Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors (J Clin Oncol. 2020 Jun 22; JCO1902404. doi: 10.1200/JCO.19.02404.)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4